Table 2.
Ocular adverse events in eyes treated with brolucizumab
| Type of adverse event | Classification of IOI-related AE | n (%) |
|---|---|---|
| Eyes with IOI-related AEs* | 22/482 (4.6) | |
| Posterior uveitis | IOI | 5 (1.0) |
| Anterior uveitis | IOI | 4 (0.8) |
| Panuveitis | IOI | 4 (0.8) |
| Endophthalmitis | IOI | 2 (0.4) |
| Vitritis | IOI | 2 (0.4) |
| Corneal edema and persistent elevated IOP | IOI | 1 (0.2) |
| Vasculitis | IOI + RV | 1 (0.2) |
| Vasculitis and anterior uveitis | IOI + RV | 1 (0.2) |
| Vasculitis and vascular occlusion | IOI + RV + RO | 1 (0.2) |
| Vascular occlusion and vasculitis and panuveitis | IOI + RV + RO | 1 (0.2) |
| Eyes with non-IOI-related AEs | 6/482 (1.2) | |
| Hemorrhage (submacular/subretinal) | – | 2 (0.4) |
| Thygeson’s superficial punctate keratitis | – | 1 (0.2) |
| Retinal detachment | – | 1 (0.2) |
| Macular hole | – | 1 (0.2) |
| Visually significant floaters | – | 1 (0.2) |
*Eyes experiencing multiple concurrent events are listed only once under the combined AE
AE, adverse event; IOI, intraocular inflammation